Niagen Bioscience Execs to Highlight Longevity Investment Case at Gstaad Conference
Event summary
- Niagen Bioscience CEO Rob Fried and CFO Ozan Pamir to present at Longevity Investors Conference in Gstaad, Switzerland, September 14–17, 2026.
- Fried to participate in 'Longevity Goes Mainstream' panel on September 16.
- Management team to hold one-on-one investor meetings during the event.
- Attendees to sample Tru Niagen and Niagen Plus products on-site.
- Conference features institutional investors, family offices, and leading longevity scientists.
The big picture
Niagen Bioscience's participation in the Longevity Investors Conference underscores the growing mainstream interest in healthy aging and NAD+ science. The event provides a platform for the company to showcase its leadership in the space and potentially secure partnerships or investments. As the longevity market continues to expand, Niagen's ability to differentiate its products and scientific research will be critical to its long-term success.
What we're watching
- Investor Sentiment
- Whether Niagen Bioscience can leverage this high-profile conference to attract significant institutional investment in its NAD+ boosting technologies.
- Product Differentiation
- How the on-site sampling of Tru Niagen and Niagen Plus will impact consumer and investor perception of the company's product portfolio.
- Regulatory Pathways
- The pace at which NAD Pharmaceuticals Corp. advances its NB4168 research, particularly in the context of accelerated aging and rare genetic diseases.